Hormonal
Metabolic surgery provides superior short-term remission of type 2 diabetes and greater weight loss compared to pharmacotherapy alone, but long-term remission rates decline significantly over time.
Metabolic surgery (like gastric bypass or sleeve gastrectomy) is currently the most effective treatment for obesity and Type 2 Diabetes, offering significantly greater weight loss and diabetes remission rates than medication alone. However, these benefits tend to fade over several years, meaning surgery is not a permanent 'cure' but a powerful tool that often requires ongoing medical management to maintain results.
Metabolic surgery is a very effective treatment for obesity with evidence from a meta-analysis of 136 studies including all types of commonly performed surgical procedures resulting in a mean absolute weight loss of −39.71 kg... Metabolic surgery is an effective option for type 2 diabetes... demonstrated in several randomized controlled trials (RCTs) with short-term follow up to be superior to medical therapy, with respect to remission of diabetes and achieving glycaemic control.
Why this rating
Supported by meta-analyses of 136 studies, prospective case-control series (Swedish Obese Subjects), and multiple RCTs (STAMPEDE, etc.).
Source
Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
Alexis Sudlow et al. · Therapeutic Advances in Endocrinology and Metabolism · 2019
DOI 10.1177/2042018819875407
More from this paper
- Long-term remission of Type 2 Diabetes following metabolic surgery is not sustained for the majority of patients, with remission rates dropping significantly after 5 years.Good
- A multimodal treatment approach combining metabolic surgery with adjuvant pharmacotherapy (specifically GLP-1 agonists or other anti-obesity drugs) is superior to surgery alone for maintaining long-term glycemic control and remission.Good
- Adjuvant pharmacotherapy with anti-obesity medications (AOMs) such as Liraglutide, Lorcaserin, or Naltrexone/Bupropion is effective and well-tolerated for managing weight regain or insufficient weight loss after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →